Go to
current issue
-
The expanding role for small molecules in immuno-oncology Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-08-18 Rienk Offringa, Lisa Kötzner, Bayard Huck, Klaus Urbahns
-
Macrophages as tools and targets in cancer therapy Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-08-16 Alberto Mantovani, Paola Allavena, Federica Marchesi, Cecilia Garlanda
-
First de novo deuterated drug poised for approval Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-08-16
Bristol Myers Squibb’s first-in-class TYK2 inhibitor and blockbuster contender deucravacitinib showcases the role for heavy hydrogen in novel drug discovery.
-
Modulating biomolecular condensates: a novel approach to drug discovery Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-08-16 Diana M. Mitrea, Matthäus Mittasch, Beatriz Ferreira Gomes, Isaac A. Klein, Mark A. Murcko
-
INCATE: a partnership to boost the antibiotic pipeline Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-08-16 Silke Alt, Douglas Haggstrom, Helmut Kessmann, Florian Kloss, Christian Elias Schneider, Timo Jäger, Torsten Schwede, Axel Brakhage, Christoph Dehio
INCATE, the INCubator for Antibacterial Therapies in Europe, aims to boost the antibiotic pipeline by accelerating the translation of academic innovation into industrial R&D projects to tackle antimicrobial resistance. Founded in 2021 as a partnership of research institutions and pharma companies, INCATE provides advice, community and non-dilutive funding to start-up companies.
-
Pharmaceutical innovation sourcing Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-08-12
Discover the world’s best science and medicine | Nature.com
-
The UK Biobank at 20 Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-08-11
The UK Biobank houses an extensive collection of biological samples and health information from 500,000 volunteers, providing clues to the genetic and environmental drivers of disease. Naomi Allen, the project’s chief scientist and an epidemiologist at Oxford University, discusses the exploding body of findings from this 20-year-old biomedical resource and the prospects for the expansion of this biopharmaceutical
-
The glymphatic system: implications for drugs for central nervous system diseases Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-08-10 Terhi J. Lohela, Tuomas O. Lilius, Maiken Nedergaard
-
Targeting RNA structures with small molecules Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-08-08 Jessica L. Childs-Disney, Xueyi Yang, Quentin M. R. Gibaut, Yuquan Tong, Robert T. Batey, Matthew D. Disney
-
BCMA-targeted bispecific gets first green light, in the EU Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-08-05
Discover the world’s best science and medicine | Nature.com
-
Biogen files ALS drug for FDA review, putting neuroscience-accelerated approvals back in the hot seat Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-08-05
Discover the world’s best science and medicine | Nature.com
-
Pliant’s integrin inhibitor boosted by phase II IPF data Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-08-05
Discover the world’s best science and medicine | Nature.com
-
A route to rational anticancer combinations Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-07-29
Discover the world’s best science and medicine | Nature.com
-
Phenotypic screen with deep learning finds cardioprotective molecules Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-07-27
Discover the world’s best science and medicine | Nature.com
-
Improving circular RNA protein yields Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-07-25
Discover the world’s best science and medicine | Nature.com
-
Targeting ALDH1B1 in colorectal cancer Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-07-25
Discover the world’s best science and medicine | Nature.com
-
Towards a universal flu vaccine Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-07-25
Discover the world’s best science and medicine | Nature.com
-
Inhibiting IgE in pulmonary hypertension Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-07-25
Discover the world’s best science and medicine | Nature.com
-
Loss of Y chromosome promotes cardiac fibrosis Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-07-20
Discover the world’s best science and medicine | Nature.com
-
Inosine boosts fat burning Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-07-20
Discover the world’s best science and medicine | Nature.com
-
Base editors hit the clinic Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-07-13
Genome-editing drugs that make precise corrections to DNA are entering clinical trials for cardiovascular and haematological diseases.
-
FDA new drug approvals in Q2 2022 Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-07-11
Discover the world’s best science and medicine | Nature.com
-
Two-pronged approach for macular degeneration Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-07-08
Discover the world’s best science and medicine | Nature.com
-
LRRK2 inhibitor progresses for Parkinson disease Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-07-08
Discover the world’s best science and medicine | Nature.com
-
Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-07-08
Discover the world’s best science and medicine | Nature.com
-
Ipsen buys Epizyme for US$247 million Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-07-06
Discover the world’s best science and medicine | Nature.com
-
FDA approves fifth RNAi drug — Alnylam’s next-gen hATTR treatment Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-07-06
Discover the world’s best science and medicine | Nature.com
-
What should go into a booster shot for COVID-19? Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-07-06
Discover the world’s best science and medicine | Nature.com
-
BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-07-06
Discover the world’s best science and medicine | Nature.com
-
Avidity in antibody effector functions and biotherapeutic drug design Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-07-05 Simone C. Oostindie, Greg A. Lazar, Janine Schuurman, Paul W. H. I. Parren
-
Improving efficacy of ASO therapy in SMA Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-07-04
Discover the world’s best science and medicine | Nature.com
-
Gut metabolite mediates nerve repair Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-07-04
Discover the world’s best science and medicine | Nature.com
-
Promoting tissue repair after heart attack Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-07-04
Discover the world’s best science and medicine | Nature.com
-
Developing bacterial PROTACs Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-07-04
Discover the world’s best science and medicine | Nature.com
-
Targeting cancers with chromosome instability Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-07-01
Discover the world’s best science and medicine | Nature.com
-
Mimicking the beneficial effects of exercise Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-06-28
Discover the world’s best science and medicine | Nature.com
-
Advancing innovative clinical trials to efficiently deliver medicines to patients Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-06-27 Robert A. Beckman, Fanni Natanegara, Pritibha Singh, Freda Cooner, Zoran Antonijevic, Yi Liu, Cristiana Mayer, Karen Price, Rui Tang, Amy Xia, Maria Apostolaros, Courtney Granville, Debra Michaels
Complex innovative designs in clinical trials have the potential to increase efficiency and lower the cost of drug development, improving patient access to therapies. This article highlights designs and approaches based on a meeting linked to an ongoing FDA pilot program in the field.
-
Antibodies to combat viral infections: development strategies and progress Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-06-20 Giuseppe Pantaleo, Bruno Correia, Craig Fenwick, Victor S. Joo, Laurent Perez
-
From pandemic preparedness to public–private partnerships Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-06-17
Julie Gerberding — incoming CEO of the Foundation for the NIH (FNIH), and former Director of the CDC and executive at Merck & Co. — discusses COVID-19 learnings, centralized clinical trials and trust in science.
-
Upcoming market catalysts in Q3 2022 Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-06-16
Discover the world’s best science and medicine | Nature.com
-
What’s next for the synthetic lethality drug discovery engine? Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-06-16
As a surge of cancer drugs with new synthetic lethality targets enter the clinic, the opportunities and challenges of the underlying discovery strategies are coming into focus.
-
Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-06-14 Tae Kon Kim, Esten N. Vandsemb, Roy S. Herbst, Lieping Chen
Tumours employ various tactics to adapt and eventually resist immune attack. These mechanisms are collectively called adaptive immune resistance (AIR). The first defined and therapeutically validated AIR mechanism is the selective induction of programmed cell death 1 ligand 1 (PDL1) by interferon-γ in the tumour. Blockade of PDL1 binding to its receptor PD1 by antibodies (anti-PD therapy) has resulted
-
Publisher Correction: Phenotypic drug discovery: recent successes, lessons learned and new directions. Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-06-10 Fabien Vincent,Arsenio Nueda,Jonathan Lee,Monica Schenone,Marco Prunotto,Mark Mercola
-
GSK buys Affinivax for up to $3.3 billion, bolstering its vaccine pipeline Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-06-09
Discover the world’s best science and medicine | Nature.com
-
BMS buys Turning Point Therapeutics and its kinase inhibitors for $4.1 billion Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-06-09
Discover the world’s best science and medicine | Nature.com
-
Novel antibiotics from bacterial blueprints Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-06-09
Discover the world’s best science and medicine | Nature.com
-
Vaccine exposes tumours to immune cell attack Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-06-09
Discover the world’s best science and medicine | Nature.com
-
A bacteria-derived oral tumour vaccine Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-06-08
Discover the world’s best science and medicine | Nature.com
-
Restoring memory in aged mice Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-06-08
Discover the world’s best science and medicine | Nature.com
-
Ketone body blocks intestinal tumour growth Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-06-08
Discover the world’s best science and medicine | Nature.com
-
Plant protein blocks tumour growth Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-06-08
Discover the world’s best science and medicine | Nature.com
-
Promoting efferocytosis heals diabetic wounds Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-06-07
Discover the world’s best science and medicine | Nature.com
-
Thinking outside the box: non-canonical targets in multiple sclerosis Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-06-06 Laura Bierhansl, Hans-Peter Hartung, Orhan Aktas, Tobias Ruck, Michael Roden, Sven G. Meuth
Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system that causes demyelination, axonal degeneration and astrogliosis, resulting in progressive neurological disability. Fuelled by an evolving understanding of MS immunopathogenesis, the range of available immunotherapies for clinical use has expanded over the past two decades. However, MS remains an incurable disease and
-
A nuclease inhibitor for neurodegeneration Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-06-01
Discover the world’s best science and medicine | Nature.com
-
Drugging the efferocytosis process: concepts and opportunities Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-06-01 Parul Mehrotra, Kodi S. Ravichandran
The daily removal of billions of apoptotic cells in the human body via the process of efferocytosis is essential for homeostasis. To allow for this continuous efferocytosis, rapid phenotypic changes occur in the phagocytes enabling them to engulf and digest the apoptotic cargo. In addition, efferocytosis is actively anti-inflammatory and promotes resolution. Owing to its ubiquitous nature and the sheer
-
Landscape of cancer cell therapies: trends and real-world data Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-06-01
Discover the world’s best science and medicine | Nature.com
-
Engineering the next generation of cell-based therapeutics Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-05-30 Caleb J. Bashor, Isaac B. Hilton, Hozefa Bandukwala, Devyn M. Smith, Omid Veiseh
Cell-based therapeutics are an emerging modality with the potential to treat many currently intractable diseases through uniquely powerful modes of action. Despite notable recent clinical and commercial successes, cell-based therapies continue to face numerous challenges that limit their widespread translation and commercialization, including identification of the appropriate cell source, generation
-
Phenotypic drug discovery: recent successes, lessons learned and new directions Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-05-30 Fabien Vincent, Arsenio Nueda, Jonathan Lee, Monica Schenone, Marco Prunotto, Mark Mercola
Many drugs, or their antecedents, were discovered through observation of their effects on normal or disease physiology. For the past generation, this phenotypic drug discovery approach has been largely supplanted by the powerful but reductionist approach of modulating specific molecular targets of interest. Nevertheless, modern phenotypic drug discovery, which combines the original concept with modern
-
Lilly’s tirzepatide secures first approval in diabetes, paving path for dual-acting hormone mimetics Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-05-20
Discover the world’s best science and medicine | Nature.com
-
Pfizer buys Biohaven’s migraine drugs for $11.6 billion Nat. Rev. Drug. Disc. (IF 112.288) Pub Date : 2022-05-20
Discover the world’s best science and medicine | Nature.com
更新日期：2022-07-06
Copyright © 2014-2022 北京衮雪科技有限公司 All Rights Reserved
京ICP备11026495-2号
京公网安备 11010802027423号
京公网安备 11010802027423号